Caffeine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Caffeine: From Headache and Rhinitis Conditions to Nasal Cavity Disease
One-Sentence Summary
Caffeine is originally associated with allergic and vasomotor rhinitis, migraine, cluster headache and related headache disorders, as well as pharyngitis and the common cold. The TxGNN model predicts it may be effective for nasal cavity disease, but there are currently 0 clinical trials and only 3 publications (a review, a preclinical formulation study and an off-topic animal study), none showing benefit in nasal disease. This is a model prediction with very limited supporting evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, vasomotor rhinitis, migraine, pharyngitis, common cold, cluster headache and other headache disorders (from the knowledge graph; the single New Zealand licence lists no indication text) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L4 |
| New Zealand Market Status | Cancelled only |
| Number of Authorizations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Caffeine is an adenosine receptor antagonist (A1, A2A, A2B and A3) and also acts on intracellular calcium-release channels (IP3R1 and ryanodine receptors RyR1–3). Detailed mechanism-of-action data beyond this receptor pharmacology are not available.
The predicted indication is related to the original indications of allergic and vasomotor rhinitis, which are nasal conditions. Bitter taste receptors are also expressed in airway and nasal tissue and may mediate responses to caffeine, and a nasal caffeine gel has been studied as a delivery route for cognition after sleep deprivation.
However, none of this shows therapeutic benefit in nasal disease itself. Rhinitis as an original indication does not establish efficacy for the broad "nasal cavity disease" category, so the prediction should be treated as a hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26272040 | 2015 | Review | Pharmacology & Therapeutics | Bitter taste receptors are expressed in the nasal cavity and lungs, among other tissues; their role in human airways is still unclear |
| 35579146 | 2022 | Preclinical formulation study | Current Drug Delivery | Nasal caffeine thermo-sensitive in situ gel studied for cognition after sleep deprivation, not for nasal disease |
| 9751618 | 1998 | Animal study | Cancer Research | Black tea and caffeine inhibited lung tumours in rats; off-topic for nasal disease |
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 461253 (cancelled) | Biomed | Oral liquid 20 mg/ml (10 mg base/ml) | Not recorded |
Safety Considerations
- Contraindications (from knowledge-graph drug-disease links, not label text): Cardiovascular and blood pressure conditions (hypertension, orthostatic hypotension, postural orthostatic tachycardia syndrome, multiple system atrophy, long QT syndromes); neurological and psychiatric conditions (epilepsy, insomnia, anxiety and related disorders, dysthymic disorder); liver, kidney, gallbladder and pancreatic disease (including liver failure); gastrointestinal disease (gastric and peptic ulcer, inflammatory bowel disease); respiratory disease (COPD); thyroid disease (hypothyroidism, myxedema); porphyria; thrombocytopenia.
- Drug Interactions: The interaction query returned 8 records, all pharmacological target bindings rather than drug-drug interactions: adenosine receptors A1, A2A, A2B and A3, IP3 receptor 1, and ryanodine receptors 1–3. No specific interacting drugs or severity levels were identified.
- Other concerns from the literature: Caffeine may contribute to medication-overuse and analgesic-induced headache.
Please refer to the package insert for authoritative warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but there are no clinical trials and the literature shows no benefit of caffeine in nasal cavity disease. The only New Zealand licence is cancelled, and label-based safety data were not available.
To proceed, the following is needed:
- A more specific nasal indication (for example, allergic or vasomotor rhinitis) with a defined mechanism and route
- Controlled clinical or well-designed preclinical evidence in nasal disease
- Medsafe package insert warnings and contraindications
- Detailed mechanism-of-action data
- Assessment of route and formulation, since the only New Zealand licence is an oral liquid and a nasal product would be a new formulation
Other predictions of note: Two predictions rank higher on evidence than the lead one, and both are recommended as research questions:
- Hypnic headache (score 99.17%, L4): reviews and case reports describe caffeine as a first-line option, but there are no controlled trials.
- Trigeminal autonomic cephalalgia (score 99.21%, L4): plausible, as cluster headache and paroxysmal hemicrania are already original indications, but there is no caffeine-specific controlled data.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.